logo
Terra Innovatum and GSR III Acquisition Corp. File Form S-4 After Business Combination Announcement Advancing Public Listing

Terra Innovatum and GSR III Acquisition Corp. File Form S-4 After Business Combination Announcement Advancing Public Listing

Miami Herald15-05-2025
Transaction To Accelerate Terra Innovatum's Pathway to Commercialization of Groundbreaking Micro-Modular Nuclear Technology by 2028
NEW YORK, NY AND AUSTIN, TX / ACCESS Newswire / May 15, 2025 / Terra Innovatum Srl ("Terra Innovatum," or the "Company"), a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. ("GSRT") (Nasdaq:GSRT), a publicly traded special purpose acquisition company, today announced that Terra Innovatum and GSRT have filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission. This filing marks a key milestone toward the proposed business combination and public listing, intended to accelerate the deployment of Terra Innovatum's breakthrough micro-modular reactor technology, SOLO™, and expand access to clean, scalable and reliable energy.
In Picture (Left to Right): Anantha Ramamurti, Marco Cherubini, Massimo Morichi, Gus Garcia, Cesare Frepoli, Guillaume Moyen, Giordano Morichi, Alessandro Petruzzi, Lew Silberman, Luca Longobardi, Nicholas Hresko-Staab.
The business combination aims to enable Terra Innovatum to execute its mission to deliver low-carbon, cost-efficient, and reliable power. SOLO™ is the first micro-modular reactor designed to operate on widely available Low-Enriched Uranium (LEU) and is built using commercial off-the-shelf components. This approach significantly streamlines regulatory review and reduces both technical and supply chain risks. Earlier this year, Terra Innovatum submitted its regulatory engagement plan to the Nuclear Regulatory Commission (NRC), a critical step toward its targeted commercial deployment in 2028.
PUBLIC LISTING & TRANSACTION OVERVIEW
The proposed business combination is expected to generate up to approximately $230 million in gross proceeds before accounting for redemptions and any committed financing. This transaction values Terra Innovatum at a pre-money equity value of $475 million.
Following the completion of the transaction, the combined company will be led by Terra Innovatum's current management team under the name Terra Innovatum and is expected to trade on the Nasdaq under the ticker symbol "NKLR." Terra Innovatum shareholders will roll 100% of their equity into the newly formed public entity. The transaction has been unanimously approved by the Boards of Directors of GSRT and Terra Innovatum. Closing is anticipated to occur in the second half of 2025, subject to customary closing conditions.
Further details on the proposed transaction, including a copy of the business combination agreement and investor presentation, are contained in filings with the U.S. Securities and Exchange Commission (SEC), and are available at www.sec.gov.
ABOUT TERRA INNOVATUM & SOLOTM
Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.
It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.
SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.
To learn more, visit www.x-solo.com.
IMPORTANT INFORMATION FOR SHAREHOLDERS
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.
In connection with the business combination, a to-be-formed Dutch company ("Pubco"), GSRT and Terra Innovatum (the "Registrant Parties") have filed with the SEC a registration statement on Form S-4 (the "Registration Statement"), which includes a preliminary prospectus of Pubco relating to the offer of securities to be issued in connection with the business combination, and a preliminary proxy statement of GSRT to be distributed to holders of GSRT's ordinary shares in connection with GSRT's solicitation of proxies for a vote by GSRT's shareholders with respect to the Business Combination and other matters described in the Registration Statement. The Registrant Parties also plan to file other documents with the SEC regarding the business combination. After the Registration Statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to the shareholders of GSRT. INVESTORS OF GSRT AND TERRA INNOVATUM ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS CONTAINED THEREIN (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS RELATING TO THE BUSINESS COMBINATION THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION.
Investors will be able to obtain free copies of the proxy statement/prospectus and other documents containing important information about the Registrant Parties once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. In addition, the documents filed by GSRT may be obtained free of charge by written request to GSRT at 5900 Balcones Drive, Suite 100, Austin TX 78731.
PARTICIPANTS IN THE SOLICITATION
Each of the Registrant Parties, and their respective directors and executive officers, may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of GSRT is set forth in GSRT's filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their direct and indirect interests will be set forth in the Registration Statement (and will be included in the proxy statement/prospectus) and other relevant documents when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.
FORWARD LOOKING STATEMENTS
The statements contained in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on GSRT and the other Registrant Parties. There can be no assurance that future developments affecting GSRT and the other Registrant Parties will be those that we have anticipated. These forward-looking statements speak only as of the date this press release is delivered and involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against GSRT, any of the Registrant Parties, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of GSRT or the SEC's declaration of the effectiveness of the Registration Statement (which will include the proxy statement/prospectus contained therein) to be filed by the Registrant Parties or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability of Pubco to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Terra Innovatum as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination, including the reorganization described in the business combination agreement; (9) changes in applicable laws or regulations; (10) the possibility that the Registrant Parties or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the amount of redemption requests made by GSRT shareholders and (12) other risk factors described herein as well as the risk factors and uncertainties described in the Form S-4 and GSRT's other filings with the SEC, as well as any further risks and uncertainties to be contained in the proxy statement/prospectus filed after the date hereof. In addition, there may be additional risks that neither GSRT nor any of the other Registrant Parties presently know, or that GSRT or the other Registrant Parties currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward- looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.
None of GSRT, the other Registrant Parties, or any of their respective affiliates, officers, employees or agents, makes any representation or warranty, either express or implied, in relation to the fairness, reasonableness, adequacy, accuracy, completeness or reliability of the information, statements or opinions, whichever their source, contained in this press release or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. GSRT, the other Registrant Parties and their respective affiliates, officers, employees and agents further expressly disclaim any and all liability relating to or resulting from the use of this press release and any errors therein or omissions therefrom. Further, the information contained herein is preliminary, is provided for discussion purposes only, is only a summary of key information, is not complete and is subject to change without notice.
In addition, the information contained in this press release is provided as of the date hereof and may change, and neither GSRT nor the other Registrant Parties undertakes any obligation to update or revise any forward- looking statements, whether as a result of new information, inaccuracies, future events or otherwise, except as may be required under applicable securities laws.
CONTACTS
Giordano MorichiPartner, Chief Business Development Officer & Investor RelationsTerra Innovatum SrlE: g.morichi@terrainnovatum.comW: www.x-solo.com
Anantha RamamurtiPresident, Chief Financial OfficerGSR III Acquisition CorpE: anantha@gsrspac.comP: (949) 468-7434
Nicholas Hresko-StaabMedia RelationsAlliance Advisors IRE: TerraIR@allianceadvisors.com
SOURCE: TERRA INNOVATUM SRL
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tesla (TSLA) Shares Jump After China Sales Break 8-Month Losing Streak
Tesla (TSLA) Shares Jump After China Sales Break 8-Month Losing Streak

Yahoo

time7 minutes ago

  • Yahoo

Tesla (TSLA) Shares Jump After China Sales Break 8-Month Losing Streak

July 2 - Tesla (NASDAQ:TSLA) shares jumped more than 5% on Wednesday after the company reported a 0.8% year?on?year rise in China?made electric vehicle sales for June, ending an eight?month slide. Deliveries from the Shanghai factory, including domestic sales and exports, totalled 71,599 units, up from May's pace by about 16%, data from the China Passenger Car Association showed. The recovery remains modest compared with local rivals. BYD (BYDDF) delivered a record 382,585 vehicles in June, up roughly 10% year?over?year, while NIO (NYSE:NIO) logged a 17.5% increase to 24,925 units. XPeng (NYSE:XPEV) saw the strongest growth, with sales surging 224% to 34,611 cars. In Europe, Tesla faces steeper challenges, with registrations in Denmark and Sweden plunging more than 60% last month. Investors await Tesla's Q2 delivery figures due later today, with the company's earnings report scheduled in the coming weeks. Seeking Alpha's Cavenagh Research forecasts a disappointing quarter for the Texas?based automaker. Despite competitive pressure, Tesla's slight rebound in its largest market may offer a foundation for its upcoming quarterly updates. This article first appeared on GuruFocus. Sign in to access your portfolio

Jim Cramer on TG Therapeutics: 'You Should Buy the Stock'
Jim Cramer on TG Therapeutics: 'You Should Buy the Stock'

Yahoo

time12 minutes ago

  • Yahoo

Jim Cramer on TG Therapeutics: 'You Should Buy the Stock'

TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 14 stocks Jim Cramer recently looked at. When a caller inquired about the company during the lightning round, Cramer stated: 'I remember when Mike Weiss was an analyst. I always loved the man. I love him now. I think you should buy the stock.' A scientific researcher holding a petri dish containing a glycoengineered monoclonal antibody. TG Therapeutics, Inc. (NASDAQ:TGTX) develops and commercializes therapies for B-cell mediated diseases, and it offers BRIUMVI for multiple sclerosis and is advancing a pipeline of monoclonal antibodies and kinase inhibitors targeting autoimmune conditions and blood cancers. ClearBridge Investments stated the following regarding TG Therapeutics, Inc. (NASDAQ:TGTX) in its Q4 2024 investor letter: '2024 proved a particularly active year for new idea generation: we added 23 new investments while exiting 29 due to a variety of considerations, including acquisitions, market capitalization constraints, and our assessment of forward return potential. While many of the new investments we made during the year are of relatively modest size, we will continue to build these positions over time provided company execution and end market prospects remain intact. In the fourth quarter we initiated five new investments: Oscar Health,TG Therapeutics, Inc. (NASDAQ:TGTX), Clearwater Analytics, Fluor and Modine. While we acknowledge the potential of TGTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Jim Cramer Says 'CoreWeave is Too High'
Jim Cramer Says 'CoreWeave is Too High'

Yahoo

time12 minutes ago

  • Yahoo

Jim Cramer Says 'CoreWeave is Too High'

CoreWeave, Inc. (NASDAQ:CRWV) is one of the 14 stocks Jim Cramer recently looked at. During the episode, Cramer mentioned that the stock has a lot of short sellers, as he commented: 'They think they may have another CoreWeave on their hands, that's a data center play that has 361 million shares, only 46 million are free to trade. When there are so few shares, it's very easy for buyers to annihilate the short sellers who bet against these stocks, and there are plenty of short sellers here. Considerable short, for instance, in CoreWeave, 31% of the float. That's kind of reminiscent of the old GameStop in a meme stock heyday… A portfolio manager analyzing a stock chart, seeking to find the right investments. CoreWeave (NASDAQ:CRWV) provides cloud infrastructure tailored for generative AI and offers compute, storage, networking, and managed services to support enterprise workloads. Additionally, the company delivers tools for AI training, rendering, and machine learning optimization. While we acknowledge the potential of CRWV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store